{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:47:43Z","timestamp":1764510463977,"version":"3.40.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.nucmedbio.2013.09.001","type":"journal-article","created":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T16:51:12Z","timestamp":1381337472000},"page":"1-9","source":"Crossref","is-referenced-by-count":9,"title":["[18F]Altanserin and small animal PET: Impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT2A receptor densities in the rat brain"],"prefix":"10.1016","volume":"41","author":[{"given":"Tina","family":"Kroll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Elmenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Matusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Avdo","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Wedekind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Weisshaupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0005","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/jps.23575","article-title":"Quantitative atlas of blood\u2013brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset","volume":"102","author":"Hoshi","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/138920111795164020","article-title":"ABC transporters in the CNS\u2014an inventory","volume":"12","author":"Hartz","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0015","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00259-006-0296-y","article-title":"Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus\/infusion approach","volume":"34","author":"Haugbol","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0020","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/01.WCB.0000074092.59115.23","article-title":"Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus\/infusion approach","volume":"23","author":"Pinborg","year":"2003","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1007\/s11307-013-0621-3","article-title":"Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models","author":"Kroll","year":"2013","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0030","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/jcbfm.2011.94","article-title":"Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling","volume":"31","author":"Riss","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.biopsych.2007.07.009","article-title":"Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder","volume":"63","author":"Frokjaer","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-007-0921-x","article-title":"5-HT2A receptor density is decreased in the at-risk mental state","volume":"195","author":"Hurlemann","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0045","first-page":"106","article-title":"5-HT2A antagonists in psychiatric disorders","volume":"3","author":"de Angelis","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0055","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/1078-0432.CCR-04-1725","article-title":"Cyclosporin a is a broad-spectrum multidrug resistance modulator","volume":"11","author":"Quadir","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0060","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00259-008-0832-z","article-title":"Cyclosporin, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies","volume":"35","author":"Lacan","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/syn.20348","article-title":"Effect of a P-glycoprotein inhibitor, cyclosporin a, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(\u2013\u2013)-WAY","volume":"61","author":"Liow","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1124\/dmd.108.024745","article-title":"Species differences in blood\u2013brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport","volume":"37","author":"Syv\u00e4nen","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0075","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1002\/jps.21359","article-title":"Pharmacokinetics of P-Glycoprotein inhibition in the rat blood\u2013brain barrier","volume":"97","author":"Syv\u00e4nen","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0080","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0085","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.apradiso.2006.03.005","article-title":"No-carrier-added nucleophilic 18F-labelling in an electrochemical cell exemplified by the routine production of [18F]altanserin","volume":"64","author":"Hamacher","year":"2006","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.neuroimage.2006.05.047","article-title":"Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood\u2013brain barrier can be studied with PET","volume":"32","author":"Syv\u00e4nen","year":"2006","journal-title":"NeuroImage"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00004647-200304000-00014","article-title":"Absolute cerebral blood volume and blood flow measurements based on synchrotron radiation quantitative computed tomography","volume":"23","author":"Adam","year":"2003","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00004647-200106000-00002","article-title":"Positron emission tomography compartmental models","volume":"21","author":"Gunn","year":"2001","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0185","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","article-title":"Graphical analysis of reversible radioligand binding from time\u2013activity measurements applied to [N-11C-methyl]-(\u2212)-cocaine PET studies in human subjects","volume":"10","author":"Logan","year":"1990","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0190","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/00004647-200210000-00015","article-title":"Strategies to improve neuroreceptor parameter estimation by linear regression analysis","volume":"22","author":"Ichise","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET recptor studies","volume":"4","author":"Lammertsma","year":"1996","journal-title":"NeuroImage"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0200","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/00004647-200212000-00004","article-title":"Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging","volume":"22","author":"Wu","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0205","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","article-title":"Distribution volume ratios without blood sampling from graphical analysis of PET data","volume":"16","author":"Logan","year":"1996","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0210","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/01.WCB.0000085441.37552.CA","article-title":"Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain","volume":"23","author":"Ichise","year":"2003","journal-title":"J Cereb Blood Flow Metab"},{"year":"1998","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","key":"10.1016\/j.nucmedbio.2013.09.001_bb0095"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0006-8993(85)90857-1","article-title":"Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors","volume":"346","author":"Pazos","year":"1985","journal-title":"Brain Res"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0105","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0969-8051(97)00054-1","article-title":"In vivo binding of [18F]altanserin to rat brain 5HT2 receptors: a film and electronic autoradiographic study","volume":"24","author":"Biver","year":"1997","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0361-9230(99)00278-6","article-title":"Cellular localization of serotonin2A (5HT2A) receptors in the rat brain","volume":"51","author":"Xu","year":"2000","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0031-6997(24)01513-8","article-title":"Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations","volume":"53","author":"Lee","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/jcbfm.1995.99","article-title":"Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls","volume":"15","author":"Sadzot","year":"1995","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0125","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S1053-8119(03)00405-1","article-title":"Quantitative assessment of P-glycoprotein function in the rat blood\u2013brain barrier by distribution volume of [11C]verapamil measured with PET","volume":"20","author":"Bart","year":"2003","journal-title":"NeuroImage"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependant transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0135","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2967\/jnumed.108.051235","article-title":"Tariquidar-induced P-glycoprotein inhibition at the rat blood\u2013brain barrier studied with (R)-11C-verapamil and PET","volume":"49","author":"Bankstahl","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0140","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00259-009-1332-5","article-title":"Dose\u2013response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood\u2013brain barrier using (R)-[11C]verapamil PET","volume":"37","author":"Kuntner","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0145","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1021\/jm900940f","article-title":"Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood\u2013brain barrier","volume":"52","author":"D\u00f6rner","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"L\u00f6scher","year":"2005","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.toxlet.2010.04.025","article-title":"Efflux mechanisms at the devoloping brain barriers: ABC-transporters in the fetal and postnatal rat","volume":"197","author":"Ek","year":"2010","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0160","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.phrs.2009.02.007","article-title":"Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human","volume":"59","author":"Warren","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3835(99)00182-2","article-title":"Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR","volume":"146","author":"de Bruin","year":"1999","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nucmedbio.2013.09.001_bb0170","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805113001789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805113001789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T16:22:10Z","timestamp":1746030130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805113001789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0969805113001789"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.09.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}